300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Social Impact
Oil and Gas
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
Mobile Apps
LGBT
Life Science
Celebrity
Wine and Spirits
Climate
Music
Food and Beverage
Art
Real Estate
Sporting Goods
Publishing
Manufacturing
Digital Media
FinTech
Finance
Franchise
Financial Services
Social Media
Mobile Advertising
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Proptech
Enterprise
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Mexico
Nigeria
Russian Federation
Togo
Tunisia
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Sweden
Romania
Zimbabwe
Zambia
Norway
Tajikistan
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United Kingdom
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Argentina
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Bangladesh
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Barwell Plc, VC Fund

Barwell Plc

VC Fund

Barwell Plc is a VC fund focused on Software and Health Care. Barwell is a privately-funded venture capital company that is based in Glasgow, Scotland.

Total investments:
7
Last investment:
Lead investor:
0%

Last updated:

Industries Barwell Plc invests in

SoftwareHealth CareBiotechnologyMedical DeviceInformation Technology

Stages Barwell Plc invests in

Series ASeries BFunding RoundAngel

Countries Barwell Plc invests in

United Kingdom

Round sizes

Series A $3M–$4.3MSeries B $1.7M–$6.4M

Round size

Series A
$3M–$4.3M
Series B
$1.7M–$6.4M

Investment Focus

Industry

  • Software 2 (29%)
  • Health Care 2 (29%)
  • Biotechnology 2 (29%)
  • Medical Device 2 (29%)
  • Information Technology 2 (29%)
See all 11 industries →

Stage

  • Series A 2 (29%)
  • Series B 2 (29%)
  • Funding Round 2 (29%)
  • Angel 1 (14%)

Investments

CompanyDescriptionRoundLinks
MGB Biopharma MGB Biopharma
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection $1.7M / Sep 14, 2018
Lamellar Biomedical Lamellar Biomedical
Lamellar Biomedical Ltd was established in June 2007 when the founding Directors of the Company, recognising the considerable therapeutic potential of Lamellasomes™, acquired the intellectual property rights to the technology. $3M / Jul 24, 2015
MGB Biopharma MGB Biopharma
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection $6.4M / Series B / Sep 17, 2014
Connect-In Ltd Connect-In Ltd
Connect-In Ltd. stands for innovative Bluetooth IoT solutions, sustainable development, and state-of-the art design. Their sensors are built to be long lasting and power efficient (lasts 1-4 years on replaceable coin cell batteries) to make IoT understandable, accessible, and affordable, and to power the next generation of the Internet of Things. Angel / Apr 30, 2014
Lamellar Biomedical Lamellar Biomedical
Lamellar Biomedical Ltd was established in June 2007 when the founding Directors of the Company, recognising the considerable therapeutic potential of Lamellasomes™, acquired the intellectual property rights to the technology. $4.3M / Series A / Jan 07, 2013
MGB Biopharma MGB Biopharma
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection $3M / Series A / Mar 31, 2010
Factonomy Factonomy
Founded in 2003 by Graeme Bryce and Dave Reynolds, Factonomy licenses its technology framework to companies to help them reduce the time and cost it takes to develop applications. Factonomy's agile software environment enables the rapid development of web-enabled business applications using declarative XML only. Unlike other developmentplatforms, the Factonomy Framework allows developers to work independently on functionality, content and style, providing a coherent end-to-end environment so they can deliver solutions which are flexible and cost effective. $1.7M / Series B / May 30, 2008

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Social Impact
Oil and Gas
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
Mobile Apps
LGBT
Life Science
Celebrity
Wine and Spirits
Climate
Music
Food and Beverage
Art
Real Estate
Sporting Goods
Publishing
Manufacturing
Digital Media
FinTech
Finance
Franchise
Financial Services
Social Media
Mobile Advertising
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Proptech
Enterprise
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Mexico
Nigeria
Russian Federation
Togo
Tunisia
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Sweden
Romania
Zimbabwe
Zambia
Norway
Tajikistan
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United Kingdom
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Argentina
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Bangladesh
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Barwell Plc invest in?

Barwell Plc invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Barwell Plc's check size?

Barwell Plc typically joins rounds of $3M–$4.3M at Series A and $1.7M–$6.4M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Barwell Plc participates in.

When did Barwell Plc last invest?

The most recent investment recorded for Barwell Plc closed in Sep 2018. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Barwell Plc Barwell Plc Find emails